

Stm 天主教聖馬爾定醫院

食道癌化療處方集

最初出版日期：99.01

最後更新日期：115.02

癌別：食道癌	
CCRT	<p>(1) Cisplatin 30mg/m² (N/S 500 c.c.; ≥ 3hrs) + 5-FU 600 mg/m² (N/S 500 c.c.; ≥ 3hrs) + Leucovorin 100 mg (N/S 500 c.c.; ≥ 3hrs) / wk (during R/T treatment)</p> <p>(2) (A)←→(B) q 2 wks</p> <p>(A) Cisplatin 60 mg/m² (N/S 500 c.c.; ≥ 4hrs) + MTX 200 mg/m² (N/S 500 c.c.; ≥3hrs) (or 100 mg/m² (N/S 100 c.c.; 1 hr) for poor P.S.)</p> <p>(B) Epirubicin 50 mg/m² (N/S 100 c.c.;30 mins)+ Bleomycin 8 mg/m² (N/S 100 c.c.; 30 mins) + 5-FU 1500 mg/m² (N/S 500 c.c.; ≥ 4hrs) + Leucovorin 200 mg (N/S 500 c.c.; ≥ 4hrs) (Gastrointestinal Cancer Research 2008 Mar-Apr.; 2(2):85-92)</p>
Neoadjuvant(術前)	<p>(1) Cisplatin 60 mg/m² (N/S 500 c.c.; ≥ 4hrs) + 5-FU 2000 mg/m² (N/S 500 c.c.; ≥ 4hrs) + Leucovorin 200 mg (N/S 500 c.c.; ≥ 4hrs) q 4 wks (European Journal of Cancer Vol.33 July 1997 pp.1216-1220) or Cisplatin 60 mg/m² (N/S 500 c.c.; ≥ 4hrs) + [5-FU 1000 mg/m² (N/S 500 c.c.; ≥ 4hrs) + Leucovorin 100 mg (N/S 500 c.c.; ≥ 4hrs)] * II q 4 wks</p> <p>(2) (A)←→(B) q 2 wks</p> <p>(A) Cisplatin 60 mg/m² + MTX 200 mg/m² (N/S 500 c.c.; ≥3hrs) (or 100 mg/m² (N/S 100 c.c.; 1 hr) for poor P.S.)</p> <p>(B) Epirubicin 50 mg/m² (N/S 100 c.c.;30 mins)+ Bleomycin 8 mg/m² (N/S 100 c.c.; 30 mins)+ 5-FU 1500 mg/m² (N/S 500 c.c.; ≥ 4hrs) + Leucovorin 200 mg (N/S 500 c.c.; ≥ 4hrs) (Gastrointestinal Cancer Research 2008 Mar-Apr.; 2(2):85-92)</p>

	<p>(3) Docetaxel 60,75mg/ m² (N/S 100 c.c.; 1hr)/ 4wks or 35,40 mg/m² (N/S 100 c.c.; 1hr)/ 2 wks (only for E-G junction adenocarcinoma, ≥ stage IIB) (JCO, Nov. 2006 4991-4997)</p> <p>(4) Cisplatin(劑量同上)+ Docetaxel(劑量同上) (for E-G junction adenocarcinoma, ≥ stage IIB)</p>
<p>Adjuvant(術後)</p>	<p>(1) Cisplatin 60 mg/m² (N/S 500 c.c.; ≥ 4hrs) + 5-FU 2000 mg/m² (N/S 500 c.c.; ≥ 4hrs) + Leucovorin 200 mg (N/S 500 c.c.; ≥ 4hrs) q 4 wks *6 cycles (European Journal of Cancer Vol.33 July 1997 pp.1216-1220) or Cisplatin 60 mg/m² (N/S 500 c.c.; ≥ 4hrs) + [5-FU 1000 mg/m² (N/S 500 c.c.; ≥ 4hrs) + Leucovorin 100 mg (N/S 500 c.c.; ≥ 4hrs)] * II q 4 wks</p> <p>(2) (A)←→(B) q 2 wks *6 cycles</p> <p>(A) Cisplatin 60 mg/m² + MTX 200 mg/m² (N/S 500 c.c.; ≥3hrs) (or 100 mg/m² (N/S 100 c.c.; 1 hr) for poor P.S.)</p> <p>(B) Epirubicin 50 mg/m² (N/S 100 c.c.;30 mins)+ Bleomycin 8 mg/m² (N/S 100 c.c.; 30 mins)+ 5-FU 1500 mg/m² (N/S 500 c.c.; ≥ 4hrs) + Leucovorin 200 mg (N/S 500 c.c.; ≥ 4hrs) (Gastrointestinal Cancer Research 2008 Mar-Apr.; 2(2):85-92)</p> <p>(3) Docetaxel 60,75mg/ m² (N/S 100 c.c.; 1hr)/ 4wks or 35,40 mg/m² (N/S 100 c.c.; 1hr)/ 2 wks *6 cycles (only for E-G junction adenocarcinoma, ≥ stage IIB) (JCO, Nov. 2006 4991-4997)</p> <p>(4) Cisplatin(劑量同上)+ Docetaxel(劑量同上) *6 cycles (for E-G junction adenocarcinoma, ≥ stage IIB)</p>
<p>Palliative(無法手術)</p>	<p>(1) Cisplatin 60 mg/m² (N/S 500 c.c.; ≥ 4hrs) + 5-FU 2000 mg/m² (N/S 500 c.c.; ≥ 4hrs) + Leucovorin 200 mg (N/S 500 c.c.; ≥ 4hrs) q 4 wks (European Journal of Cancer Vol.33 July 1997 pp.1216-1220) or Cisplatin 60 mg/m² (N/S 500 c.c.; ≥ 4hrs) + [5-FU 1000 mg/m² (N/S 500 c.c.; ≥ 4hrs) + Leucovorin 100 mg (N/S 500 c.c.; ≥ 4hrs)] * II q 4 wks</p> <p>(2) (A)←→(B) q 2 wks</p> <p>(A) Cisplatin 60 mg/m² + MTX 200 mg/m² (N/S 500 c.c.; ≥3hrs) (or 100 mg/m² (N/S 100 c.c.; 1 hr) for poor P.S.)</p>

	<p>(B) Epirubicin 50 mg/m² (N/S 100 c.c.;30 mins)+ Bleomycin 8 mg/m² (N/S 100 c.c.; 30 mins)+ 5-FU 1500 mg/m² (N/S 500 c.c.; ≥ 4hrs) + Leucovorin 200 mg (N/S 500 c.c.; ≥ 4hrs) (Gastrointestinal Cancer Research 2008 Mar-Apr.; 2(2):85-92)</p> <p>(3) Docetaxel 60,75mg/ m² (N/S 100 c.c.; 1hr)/ 4wks or 35,40 mg/m² (N/S 100 c.c.; 1hr)/ 2 wks (only for E-G junction adenocarcinoma, ≥ stage IIB) (JCO, Nov. 2006 4991-4997)</p> <p>(4) Cisplatin(劑量同上)+ Docetaxel(劑量同上) (for E-G junction adenocarcinoma, ≥ stage IIB)</p> <p>(5) Nivolumab 240mg(in N/S 100ml, ivd 60mins) q2wk x 2yr.</p>
<p>May consider :</p> <ul style="list-style-type: none"> *MMC 8 mg / m² /cycle (Oncology 1993 Apr;50 Supp1 1:53-60) * Irinotecan 140,150,160 mg / m² / 2 wks (Oncology Dec.3 2000) *Cetuximab 250 mg / m² /dose (The Oncologist July 25,2005) 	

Immunotherapy: PD-1, PD-L1 抑制劑 (如 atezolizumab 、 nivolumab 、 Pembrolizumab 、 avelumab)(1091101)